More articles from From the Editor
- Localized dead bone, a potential hint to an underlying condition
The discovery of osteonecrosis by imaging, whether the patient is symptomatic or not, warrants consideration for the presence of an underlying condition.
- Pseudocellulitis, a vague term for a specific diagnostic challenge
There are infectious, vascular, and inflammatory conditions that can mimic cellulitis sufficiently to prompt admission and initial treatment with intravenous antibiotics.
- ‘Even when the wound is healed, the scar remains’
Persistent or repetitive inflammatory or ischemic insults to internal organs may lead to progressive scarring that culminates in organ failure.
- ‘All that wheezes is not asthma’—a reminder that the physical examination
In the evaluation of a patient with undefined respiratory symptoms, the physical examination can provide clues to the diagnosis and direct further testing.
- Getting stuck on a name: An example of an eponymous syndrome
Debate continues about whether we should continue to use eponymous diagnostic nomenclature or shift entirely to an anatomic or pathophysiologic descriptive terminology.
- A new direction in pain management?
It would be nice to have a treatment option for pain that is less limited by side effects, cognitive dysfunction, addiction potential, and red tape.
- More on the myths and perceived magic of corticosteroids
It is widely accepted that corticosteroids can partially prevent infusion reactions to intravenous diagnostic and therapeutic agents, but evidence to support this concept is scant.
- Diabetes: Putting off until tomorrow what could happen today can be good
Prevention of beta-cell loss and preservation of endogenous insulin production have been attractive treatment prerogatives in type 1 diabetes.
- Lipoprotein ‘little a’: More than a little target in the management of cardiovascular risk?
Lipoprotein(a) was once believed to play no contributory role in the development of cardiovascular disease. That storyline has since flipped.
- No surprise, all inflammation is not created equal as it relates to cardiovascular disease
It is accepted that inflammation is an important component of atherosclerotic cardiovascular disease, but have we found the right inflammatory target for pharmacologic therapy?